Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Immunogen Inc

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 30, 2023 4:42pm

108 Views

Post# 35762144

RE:Immunogen Inc

AbbVie plans to acquire ImmunoGen for $10.1 Billion, in a deal that would expand the Big Pharma’s presence in the oncology field and mark an exit for the 42-year-old Boston biotech. ImmunoGen was founded in 1981.

Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US, where it is marketed by Genentech, a member of the Roche Group. In October 2015, the company disclosed that Kadcyla had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer.

<< Previous

Bullboard Posts

Next >>

Yukon agency detects cyanide near Victoria Gold's Eagle mine